Stock Ratings / Health Care / RIGL / insiders

KURA (32) AKTS (41) ORIC (29) CYRX (43) ⌘ Pro Terminal →

Rigel Pharmaceuticals Inc. (RIGL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$51.45 +1.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $51.70

Rigel Pharmaceuticals Inc. (RIGL) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (93% profit margin, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate) →

ROARABLE B • BUY Cap $961.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RIGL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $51.45 (+1.40% 1D, market cap $961.1M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RIGL ranks #42 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RIGL compare to KURA and AKTS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RIGL carries a Roarable B (75/100 RQD), trailing P/E of N/A, gross margin of 93.3%, and ROIC of 28.2%. By comparison, KURA (Kura Oncology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and AKTS (Aktis Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $937.2M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while RIGL leads on capital efficiency (28.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RIGL?

▼

Per RIGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001034842), Rigel Pharmaceuticals Inc. generated $294.3M in revenue (+64.1% YoY), $367.0M in net income, and $75.7M in free cash flow against $513.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $51.70 (+0.49%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 25.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RIGL)Realized 20D OHLCV Swing Band: ±7.5%

Deterministic 5-Pillar Attribution (75/100 Composite)

🔍 WHY RIGL SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (21% of score)

20D Institutional Volume Accumulation (±7.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)

Capital intensity & 42.6% operating margin leave 7 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$48.81-4.3% Next Q

Q2 (-2Q)

Grade B$46.72+6.8% Next Q

Q3 (-1Q)

Grade B$49.91+3.1% Next Q

Current

Grade B$51.45+7.4% Hist 90D α

Trajectory: B- (67) → B (75)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RIGL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, RIGL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 90.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($47.80) or 200D SMA ($37.21) invalidates the momentum regime and cuts Target Base ($55.39) toward Bear Floor ($42.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RIGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RIGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 75%NO 25%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RIGL Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RIGL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RIGL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RIGL Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RIGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +74.17%▲ ASCENDING CHANNEL

2026-11-02O $50.74H $51.45L $50.74C $51.45VOL 159.6K

RES: $56.11SUP: $47.22SMA50: $47.80SMA200: $37.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RIGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RIGL Butterfly Map → + Track RIGL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-3.0%/yr Implied 5Y Growth

vs. +64.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RIGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RIGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RIGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RIGL)

Health Care Rank #42 of 1016 ⚔️ KURA vs RIGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RIGL vs. KURA, AKTS, ORIC, CYRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rigel Pharmaceuticals Inc. (RIGL) ranks #42 by composite RQD confidence (75/100, grade B) and #363 by equity capitalization ($961.1M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RIGL ACTIVE Rigel Pharmaceuticals Inc.	B	75/100	—	93.3%	28.2%	+1.40%	$961.1M	Benchmark Subject
KURA Kura Oncology Inc.	E	32/100	—	—	-35.0%	-1.49%	$939.4M	/kura-vs-rigl →
AKTS Aktis Oncology Inc.	D-	41/100	—	—	—	+0.18%	$937.2M	/akts-vs-rigl →
ORIC Oric Pharmaceuticals Inc.	E	29/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-rigl →
CYRX CryoPort Inc.	D-	43/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-rigl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001034842

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rigel Pharmaceuticals Inc. (RIGL) reported GAAP revenue of $294.3M (+64.1% vs. FY2024 revenue of $179.3M , and +151.8% cumulative change since FY2023) , GAAP net income of $367.0M, operating cash flow of $75.7M, and free cash flow of $75.7M (+140.4% YoY). On the balance sheet, RIGL closed FY2025 with $513.6M in total assets against $0 in total debt (Altman Z-Score: 3.64, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$294.3M	$367.0M	$75.7M	$75.7M	$513.6M	—
FY2024 (FY)	2024-12-31	$179.3M	$17.5M	$31.5M	$31.5M	$164.0M	—
FY2023 (FY)	2023-12-31	$116.9M	-$25.1M	-$5.7M	-$5.7M	—	—

3. RIGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RIGL compare to KURA and AKTS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RIGL?

Where is RIGL trading relative to its 50-day, 200-day, and 52-week technical levels?

RIGL last traded at $51.45 (+1.40% on volume of 159,584 shares), positioning the stock +7.64% above its 50-day simple moving average ($47.80) and +38.27% above its 200-day simple moving average ($37.21). Across its 52-week range of $24.95 to $52.61, RIGL sits at the 95.8% percentile with a 14-day RSI of 64.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.5% ($47.59 to $55.31).

RIGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RIGL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RIGL leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: RIGL RQD Cockpit RIGL 12M Forecast RIGL Earnings & Move RIGL Dividends & DRIP RIGL Insiders & 13F RIGL Whale Options RIGL Profit Sankey RIGL News & Why